Hookipa Pharma Inc. (HOOK) NASDAQ
$0.58 0 (0.71%)
Market Cap: $47.31M
As of 12/08/23 04:00 PM EST. Market closed.

Hookipa Pharma Inc. (HOOK)
NASDAQ
$0.58
0 (0.71%)
Market Cap: $47.31M
As of 12/08/23 04:00 PM EST. Market closed.
hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent ... read more
hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Kandera Reinhard | Chief Financial Officer | Aug 21, 2023 | Buy | $0.73 | 7,000 | 5,075 | 43,092 | Aug 22, 2023, 04:01 PM |
Kandera Reinhard | Chief Financial Officer | Aug 16, 2023 | Buy | $0.71 | 8,000 | 5,712 | 36,092 | Aug 17, 2023, 04:05 PM |
Aldag Jorn | Chief Executive Officer | Jul 11, 2023 | Buy | $0.83 | 5,000 | 4,142 | 71,952 | Jul 11, 2023, 06:21 PM |
Aldag Jorn | Chief Executive Officer | Jul 07, 2023 | Buy | $0.81 | 5,000 | 4,050 | 66,952 | Jul 11, 2023, 06:21 PM |
Aldag Jorn | Chief Executive Officer | Jul 05, 2023 | Buy | $0.89 | 5,000 | 4,450 | 61,952 | Jul 07, 2023, 05:06 PM |
Aldag Jorn | Chief Executive Officer | Jul 03, 2023 | Buy | $0.89 | 5,000 | 4,455 | 56,952 | Jul 05, 2023, 07:37 PM |
Kandera Reinhard | Chief Financial Officer | Jun 30, 2023 | Buy | $0.88 | 12,000 | 10,560 | 28,092 | Jul 03, 2023, 04:06 PM |
Orlinger Klaus | Executive VP, Research | Feb 01, 2022 | Option Exercise | $3.00 | 9,188 | 27,564 | 10,404 | Feb 01, 2022, 08:52 PM |
Baker Christine D. | Chief Business Officer | Feb 01, 2022 | Option Exercise | $3.00 | 13,658 | 40,974 | 16,158 | Feb 01, 2022, 08:50 PM |
Necina Roman | Chief Technology Officer | Feb 01, 2022 | Option Exercise | $3.00 | 12,892 | 38,676 | 14,876 | Feb 01, 2022, 08:50 PM |
Matushansky Igor | Chief Medical Officer | Feb 01, 2022 | Option Exercise | $3.00 | 14,933 | 44,799 | 100,240 | Feb 01, 2022, 08:49 PM |
Kandera Reinhard | Chief Financial Officer | Feb 01, 2022 | Option Exercise | $3.00 | 14,056 | 42,168 | 16,092 | Feb 01, 2022, 08:48 PM |
Aldag Jorn | Chief Executive Officer | Feb 01, 2022 | Option Exercise | $3.00 | 47,824 | 143,472 | 51,952 | Feb 01, 2022, 08:44 PM |
Matushansky Igor | Chief Medical Officer | Dec 21, 2021 | Option Exercise | $0.10 | 22,853 | 2,285 | 91,544 | Jan 12, 2022, 10:07 AM |
Matushansky Igor | Chief Medical Officer | Dec 21, 2021 | Sale | $2.49 | 14,949 | 37,223 | 85,307 | Jan 12, 2022, 10:07 AM |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | Apr 21, 2021 | Sale | $11.60 | 328,620 | 3,812,386 | 3,177,574 | Apr 23, 2021, 04:30 PM |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | Mar 29, 2021 | Sale | $13.67 | 36,829 | 503,570 | 3,506,194 | Mar 31, 2021, 04:06 PM |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | Mar 26, 2021 | Sale | $13.69 | 35,171 | 481,642 | 3,543,023 | Mar 31, 2021, 06:01 AM |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | Mar 25, 2021 | Sale | $13.12 | 28,546 | 374,569 | 3,578,194 | Mar 29, 2021, 04:01 PM |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | Mar 24, 2021 | Sale | $13.70 | 52,690 | 721,616 | 3,606,740 | Mar 26, 2021, 07:12 PM |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | Mar 23, 2021 | Sale | $13.91 | 40,000 | 556,476 | 3,659,430 | Mar 25, 2021, 06:13 PM |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | Mar 22, 2021 | Sale | $14.54 | 40,534 | 589,263 | 3,699,430 | Mar 24, 2021, 06:16 PM |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | Mar 19, 2021 | Sale | $14.60 | 166,230 | 2,427,739 | 3,739,964 | Mar 23, 2021, 04:31 PM |
Matushansky Igor | Chief Medical Officer | Dec 17, 2020 | Option Exercise | $0.10 | 48,988 | 4,899 | 93,881 | Dec 18, 2020, 04:04 PM |
Matushansky Igor | Chief Medical Officer | Dec 16, 2020 | Option Exercise | $0.10 | 640 | 64 | 56,774 | Dec 18, 2020, 04:04 PM |
Matushansky Igor | Chief Medical Officer | Dec 17, 2020 | Sale | $11.74 | 27,979 | 328,343 | 77,403 | Dec 18, 2020, 04:04 PM |
Matushansky Igor | Chief Medical Officer | Dec 16, 2020 | Sale | $11.70 | 380 | 4,446 | 56,394 | Dec 18, 2020, 04:04 PM |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | Oct 02, 2020 | Sale | $10.00 | 300 | 3,000 | 3,906,194 | Oct 06, 2020, 04:01 PM |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | Sep 15, 2020 | Sale | $12.61 | 41,597 | 524,477 | 3,915,755 | Sep 17, 2020, 04:02 PM |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | Jun 29, 2020 | Sale | $11.78 | 3,280 | 38,628 | 3,960,574 | Jul 24, 2020, 05:07 PM |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | Jun 29, 2020 | Sale | $11.78 | 3,280 | 38,628 | 3,960,574 | Jul 22, 2020, 04:03 PM |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | Jul 20, 2020 | Sale | $11.94 | 12,483 | 149,102 | 3,948,091 | Jul 22, 2020, 04:03 PM |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | Jun 29, 2020 | Sale | $11.78 | 3,280 | 38,628 | 3,960,574 | Jul 01, 2020, 04:16 PM |
Matushansky Igor | Chief Medical Officer | Jan 29, 2020 | Sale | $12.73 | 5,500 | 69,992 | 53,398 | Jan 31, 2020, 04:01 PM |
Lilja Anders | Sr. VP, Technical Development | Jan 23, 2020 | Option Exercise | $0.10 | 11,643 | 1,164 | 7,568 | Jan 27, 2020, 04:52 PM |
Lilja Anders | Sr. VP, Technical Development | Jan 23, 2020 | Sale | $12.59 | 11,643 | 146,533 | 0 | Jan 27, 2020, 04:52 PM |
Orlinger Klaus | Sr. VP, Research | Jan 21, 2020 | Option Exercise | $0.10 | 6,789 | 679 | 6,789 | Jan 21, 2020, 04:44 PM |
Orlinger Klaus | Sr. VP, Research | Jan 16, 2020 | Option Exercise | $0.10 | 1,711 | 171 | 1,711 | Jan 21, 2020, 04:44 PM |
Orlinger Klaus | Sr. VP, Research | Jan 21, 2020 | Sale | $12.02 | 6,789 | 81,592 | 0 | Jan 21, 2020, 04:44 PM |
Orlinger Klaus | Sr. VP, Research | Jan 16, 2020 | Sale | $11.56 | 1,711 | 19,781 | 0 | Jan 21, 2020, 04:44 PM |
Orlinger Klaus | Sr. VP, Research | Jan 14, 2020 | Option Exercise | $0.10 | 8,500 | 850 | 8,500 | Jan 16, 2020, 04:06 PM |
Orlinger Klaus | Sr. VP, Research | Jan 14, 2020 | Sale | $11.30 | 8,500 | 96,053 | 0 | Jan 16, 2020, 04:06 PM |
Matushansky Igor | Chief Medical Officer | Dec 19, 2019 | Option Exercise | $0.10 | 25,891 | 2,589 | 69,302 | Dec 23, 2019, 08:30 AM |
Matushansky Igor | Chief Medical Officer | Dec 19, 2019 | Sale | $9.93 | 10,404 | 103,312 | 58,898 | Dec 23, 2019, 08:30 AM |
Matushansky Igor | Chief Medical Officer | Dec 17, 2019 | Option Exercise | $0.10 | 26,312 | 2,631 | 54,895 | Dec 19, 2019, 04:03 PM |
Matushansky Igor | Chief Medical Officer | Dec 17, 2019 | Sale | $7.87 | 11,484 | 90,379 | 43,411 | Dec 19, 2019, 04:03 PM |
Forbion Capital Fund II Cooperatief U.A. | 10% Owner | Apr 23, 2019 | Buy | $14.00 | 53,571 | 749,994 | 2,494,173 | Apr 25, 2019, 04:15 PM |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | Apr 23, 2019 | Buy | $14.00 | 357,142 | 4,999,988 | 3,963,854 | Apr 25, 2019, 04:15 PM |
BAKER BROS. ADVISORS LP | Former 10% owner | Apr 23, 2019 | Buy | $14.00 | 892,857 | 12,499,998 | 820,729 | Apr 23, 2019, 04:54 PM |
Owner | Relationship | Date | Value($) |
Kandera Reinhard | Chief Financial Officer | 08/21/2023 | 5,075 |
Kandera Reinhard | Chief Financial Officer | 08/16/2023 | 5,712 |
Aldag Jorn | Chief Executive Officer | 07/11/2023 | 4,142 |
Aldag Jorn | Chief Executive Officer | 07/07/2023 | 4,050 |
Aldag Jorn | Chief Executive Officer | 07/05/2023 | 4,450 |
Aldag Jorn | Chief Executive Officer | 07/03/2023 | 4,455 |
Kandera Reinhard | Chief Financial Officer | 06/30/2023 | 10,560 |
Orlinger Klaus | Executive VP, Research | 02/01/2022 | 27,564 |
Baker Christine D. | Chief Business Officer | 02/01/2022 | 40,974 |
Necina Roman | Chief Technology Officer | 02/01/2022 | 38,676 |
Matushansky Igor | Chief Medical Officer | 02/01/2022 | 44,799 |
Kandera Reinhard | Chief Financial Officer | 02/01/2022 | 42,168 |
Aldag Jorn | Chief Executive Officer | 02/01/2022 | 143,472 |
Matushansky Igor | Chief Medical Officer | 12/21/2021 | 2,285 |
Matushansky Igor | Chief Medical Officer | 12/21/2021 | 37,223 |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | 04/21/2021 | 3,812,386 |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | 03/29/2021 | 503,570 |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | 03/26/2021 | 481,642 |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | 03/25/2021 | 374,569 |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | 03/24/2021 | 721,616 |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | 03/23/2021 | 556,476 |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | 03/22/2021 | 589,263 |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | 03/19/2021 | 2,427,739 |
Matushansky Igor | Chief Medical Officer | 12/17/2020 | 4,899 |
Matushansky Igor | Chief Medical Officer | 12/16/2020 | 64 |
Matushansky Igor | Chief Medical Officer | 12/17/2020 | 328,343 |
Matushansky Igor | Chief Medical Officer | 12/16/2020 | 4,446 |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | 10/02/2020 | 3,000 |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | 09/15/2020 | 524,477 |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | 06/29/2020 | 38,628 |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | 06/29/2020 | 38,628 |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | 07/20/2020 | 149,102 |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | 06/29/2020 | 38,628 |
Matushansky Igor | Chief Medical Officer | 01/29/2020 | 69,992 |
Lilja Anders | Sr. VP, Technical Development | 01/23/2020 | 1,164 |
Lilja Anders | Sr. VP, Technical Development | 01/23/2020 | 146,533 |
Orlinger Klaus | Sr. VP, Research | 01/21/2020 | 679 |
Orlinger Klaus | Sr. VP, Research | 01/16/2020 | 171 |
Orlinger Klaus | Sr. VP, Research | 01/21/2020 | 81,592 |
Orlinger Klaus | Sr. VP, Research | 01/16/2020 | 19,781 |
Orlinger Klaus | Sr. VP, Research | 01/14/2020 | 850 |
Orlinger Klaus | Sr. VP, Research | 01/14/2020 | 96,053 |
Matushansky Igor | Chief Medical Officer | 12/19/2019 | 2,589 |
Matushansky Igor | Chief Medical Officer | 12/19/2019 | 103,312 |
Matushansky Igor | Chief Medical Officer | 12/17/2019 | 2,631 |
Matushansky Igor | Chief Medical Officer | 12/17/2019 | 90,379 |
Forbion Capital Fund II Cooperatief U.A. | 10% Owner | 04/23/2019 | 749,994 |
SOFINNOVA CAPITAL VI FCPR | 10% Owner | 04/23/2019 | 4,999,988 |
BAKER BROS. ADVISORS LP | Former 10% owner | 04/23/2019 | 12,499,998 |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
BAKER BROS. ADVISORS LP | 8,065,398 | 0.03% | 82.25% | Other |
RENAISSANCE TECHNOLOGIES LLC | 555,636 | 0.00058% | -38.93% | Other |
HHLR ADVISORS, LTD. | 770,717 | 0.01% | Exited | Other |
GEODE CAPITAL MANAGEMENT, LLC | 533,113 | 0.00004% | 36.04% | Other |
BLACKROCK INC. | 295,240 | 0.00001% | 14.69% | Other |
Period of Report: 09/30/2023
10-K/10-Q Filings: View